PLAU and metabolic dysfunction-associated steatohepatitis: In support of this finding, Shalapour et al. (2017) observed an elevation of immunosuppressive IgA+ cells, interleukin 10 and programmed cell death ligand-1 in both NASH-derived HCC patients and the MUP-uPA mice that were placed on HFD.